Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance

Frances B. Maguire, Cyllene R. Morris, Arti Parikh-Patel, Rosemary D Cress, Theresa H Keegan, Chin Shang Li, Patrick S. Lin, Kenneth W Kizer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Management of advanced-stage non-small cell lung cancer (NSCLC) has changed significantly over the past two decades with the development of numerous systemic treatments, including targeted therapies. However, a high proportion of advanced-stage patients are untreated. The role that health insurance plays in receipt of systemic treatments is unclear. Methods: Using California Cancer Registry data (2012- 2014), we developed multivariable Poisson regression models to assess the independent effect of health insurance type on systemic treatment utilization among patients with stage IV NSCLC. Systemic treatment information was manually abstracted from treatment text fields. Results: A total of 17,310 patients were evaluated. Patients with Medicaid/other public insurance were significantly less likely to receive any systemic treatments [risk ratio (RR), 0.78; 95% confidence interval (CI), 0.75-0.82], bevacizumab combinations (RR, 0.57; 95% CI, 0.45-0.71), or tyrosine kinase inhibitors (RR, 0.70; 95% CI, 0.60-0.82) compared with the privately insured. Patients with Medicare or dual Medicare- Medicaid insurance were not significantly different from the privately insured in their likelihood of receiving systemic treatments. Conclusions: Substantial disparities in the use of systemic treatments for stage IV NSCLC exist by source of health insurance in California. Patients with Medicaid/other public insurance were significantly less likely to receive systemic treatments compared with their privately insured counterparts. Impact: Source of health insurance influences care received. Further research is warranted to better understand barriers to treatment that patients with Medicaid face.

Original languageEnglish (US)
Pages (from-to)1059-1066
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Health Insurance
Non-Small Cell Lung Carcinoma
Medicaid
Insurance
Therapeutics
Odds Ratio
Confidence Intervals
Medicare
Protein-Tyrosine Kinases
Registries

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance. / Maguire, Frances B.; Morris, Cyllene R.; Parikh-Patel, Arti; Cress, Rosemary D; Keegan, Theresa H; Li, Chin Shang; Lin, Patrick S.; Kizer, Kenneth W.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 6, 01.06.2019, p. 1059-1066.

Research output: Contribution to journalArticle

Maguire, Frances B. ; Morris, Cyllene R. ; Parikh-Patel, Arti ; Cress, Rosemary D ; Keegan, Theresa H ; Li, Chin Shang ; Lin, Patrick S. ; Kizer, Kenneth W. / Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 6. pp. 1059-1066.
@article{90ce2c06e3af42aa846c741290ec31af,
title = "Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance",
abstract = "Background: Management of advanced-stage non-small cell lung cancer (NSCLC) has changed significantly over the past two decades with the development of numerous systemic treatments, including targeted therapies. However, a high proportion of advanced-stage patients are untreated. The role that health insurance plays in receipt of systemic treatments is unclear. Methods: Using California Cancer Registry data (2012- 2014), we developed multivariable Poisson regression models to assess the independent effect of health insurance type on systemic treatment utilization among patients with stage IV NSCLC. Systemic treatment information was manually abstracted from treatment text fields. Results: A total of 17,310 patients were evaluated. Patients with Medicaid/other public insurance were significantly less likely to receive any systemic treatments [risk ratio (RR), 0.78; 95{\%} confidence interval (CI), 0.75-0.82], bevacizumab combinations (RR, 0.57; 95{\%} CI, 0.45-0.71), or tyrosine kinase inhibitors (RR, 0.70; 95{\%} CI, 0.60-0.82) compared with the privately insured. Patients with Medicare or dual Medicare- Medicaid insurance were not significantly different from the privately insured in their likelihood of receiving systemic treatments. Conclusions: Substantial disparities in the use of systemic treatments for stage IV NSCLC exist by source of health insurance in California. Patients with Medicaid/other public insurance were significantly less likely to receive systemic treatments compared with their privately insured counterparts. Impact: Source of health insurance influences care received. Further research is warranted to better understand barriers to treatment that patients with Medicaid face.",
author = "Maguire, {Frances B.} and Morris, {Cyllene R.} and Arti Parikh-Patel and Cress, {Rosemary D} and Keegan, {Theresa H} and Li, {Chin Shang} and Lin, {Patrick S.} and Kizer, {Kenneth W}",
year = "2019",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-18-0823",
language = "English (US)",
volume = "28",
pages = "1059--1066",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance

AU - Maguire, Frances B.

AU - Morris, Cyllene R.

AU - Parikh-Patel, Arti

AU - Cress, Rosemary D

AU - Keegan, Theresa H

AU - Li, Chin Shang

AU - Lin, Patrick S.

AU - Kizer, Kenneth W

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Management of advanced-stage non-small cell lung cancer (NSCLC) has changed significantly over the past two decades with the development of numerous systemic treatments, including targeted therapies. However, a high proportion of advanced-stage patients are untreated. The role that health insurance plays in receipt of systemic treatments is unclear. Methods: Using California Cancer Registry data (2012- 2014), we developed multivariable Poisson regression models to assess the independent effect of health insurance type on systemic treatment utilization among patients with stage IV NSCLC. Systemic treatment information was manually abstracted from treatment text fields. Results: A total of 17,310 patients were evaluated. Patients with Medicaid/other public insurance were significantly less likely to receive any systemic treatments [risk ratio (RR), 0.78; 95% confidence interval (CI), 0.75-0.82], bevacizumab combinations (RR, 0.57; 95% CI, 0.45-0.71), or tyrosine kinase inhibitors (RR, 0.70; 95% CI, 0.60-0.82) compared with the privately insured. Patients with Medicare or dual Medicare- Medicaid insurance were not significantly different from the privately insured in their likelihood of receiving systemic treatments. Conclusions: Substantial disparities in the use of systemic treatments for stage IV NSCLC exist by source of health insurance in California. Patients with Medicaid/other public insurance were significantly less likely to receive systemic treatments compared with their privately insured counterparts. Impact: Source of health insurance influences care received. Further research is warranted to better understand barriers to treatment that patients with Medicaid face.

AB - Background: Management of advanced-stage non-small cell lung cancer (NSCLC) has changed significantly over the past two decades with the development of numerous systemic treatments, including targeted therapies. However, a high proportion of advanced-stage patients are untreated. The role that health insurance plays in receipt of systemic treatments is unclear. Methods: Using California Cancer Registry data (2012- 2014), we developed multivariable Poisson regression models to assess the independent effect of health insurance type on systemic treatment utilization among patients with stage IV NSCLC. Systemic treatment information was manually abstracted from treatment text fields. Results: A total of 17,310 patients were evaluated. Patients with Medicaid/other public insurance were significantly less likely to receive any systemic treatments [risk ratio (RR), 0.78; 95% confidence interval (CI), 0.75-0.82], bevacizumab combinations (RR, 0.57; 95% CI, 0.45-0.71), or tyrosine kinase inhibitors (RR, 0.70; 95% CI, 0.60-0.82) compared with the privately insured. Patients with Medicare or dual Medicare- Medicaid insurance were not significantly different from the privately insured in their likelihood of receiving systemic treatments. Conclusions: Substantial disparities in the use of systemic treatments for stage IV NSCLC exist by source of health insurance in California. Patients with Medicaid/other public insurance were significantly less likely to receive systemic treatments compared with their privately insured counterparts. Impact: Source of health insurance influences care received. Further research is warranted to better understand barriers to treatment that patients with Medicaid face.

UR - http://www.scopus.com/inward/record.url?scp=85067176383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067176383&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-0823

DO - 10.1158/1055-9965.EPI-18-0823

M3 - Article

C2 - 30842132

AN - SCOPUS:85067176383

VL - 28

SP - 1059

EP - 1066

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -